Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
Guillain-Barré syndrome: clinical profile and management.
Fingolimod modulates microglial activation to augment markers of remyelination.
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
Poor sleep in patients with multiple sclerosis.
The value of specialty pharmaceuticals - a systematic review.
Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
Clinical profile of malay children with optic neuritis.
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Yield of emergent neuroimaging among children presenting with a first complex febrile seizure.
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.

Pages